null Journal of Pharmaceutical and Biomedical Analysis publishes results of the OMCL fingerprint study on omeprazole API samples

EDQM Strasbourg, France 02/12/2021
Journal of Pharmaceutical and Biomedical Analysis publishes results of the OMCL fingerprint study on omeprazole API samples

The Active Pharmaceutical Ingredient (API) Working Group of the General European OMCL Network (GEON) has conducted a market surveillance study on omeprazole, the results of which have been published in the Journal of Pharmaceutical and Biomedical Analysis, Vol. 208 (2021). An API fingerprint is a specific analytical profile that includes information on the physico-chemical properties of the substance. API fingerprint studies are performed in order to identify substandard or falsified APIs, which represent a threat to patient health.

In the study, OMCLs tested the pharmaceutical quality of samples, checked compliance with the monographs of the European Pharmacopoeia and used chemometric methods to process analytical fingerprints. These fingerprints could then be used to differentiate between manufacturing sources in future authenticity investigations.

You can find out more about chemometric methods in the GEON document “Benefits of Chemometrics for OMCLs”.

See also: